$33.76
-0.17[-0.50%]
At close: Apr 17
$33.76
0[0.00%]
After Hours: 4:00PM EDT
Kymera Therapeutics
(NASDAQ:KYMR)Kymera Therapeutics Stock (NASDAQ:KYMR), Analyst Ratings, Price Targets, Predictions
Kymera Therapeutics Inc has a consensus price target of $43.95, established from looking at the 51 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Piper Sandler, and JP Morgan on March 1, 2024, February 27, 2024, and February 23, 2024. With an average price target of $52.33 between Truist Securities, Piper Sandler, and JP Morgan, there's an implied 55.02% upside for Kymera Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Piper Sandler
JP Morgan
Stifel
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kymera Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/01/2024 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 59.95% | Truist Securities | Srikripa Devarakonda | $41 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 65.88% | Piper Sandler | Edward Tenthoff | $39 → $56 | Maintains | Overweight | Get Alert |
| 02/23/2024 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 39.22% | JP Morgan | Eric Joseph | $34 → $47 | Maintains | Overweight | Get Alert |
| 02/23/2024 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 62.91% | Stifel | Bradley Canino | $35 → $55 | Maintains | Buy | Get Alert |
| 02/15/2024 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 01/03/2024 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | -11.14% | B of A Securities | Geoff Meacham | $45 → $30 | Downgrade | Buy → Neutral | Get Alert |
| 12/19/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | -22.99% | Wells Fargo | Derek Archila | → $26 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/13/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | -28.91% | Morgan Stanley | James Quigley | $37 → $24 | Maintains | Equal-Weight | Get Alert |
| 11/03/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 12.56% | Piper Sandler | Edward Tenthoff | $58 → $38 | Maintains | Overweight | Get Alert |
| 11/03/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | -11.14% | HC Wainwright & Co. | Andrew Fein | $85 → $30 | Maintains | Buy | Get Alert |
| 08/29/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 9.6% | Morgan Stanley | James Quigley | $39 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/07/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 54.03% | Stifel | Bradley Canino | $48 → $52 | Maintains | Buy | Get Alert |
| 08/04/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 9.6% | Credit Suisse | Richard Law | $36 → $37 | Maintains | Neutral | Get Alert |
| 08/04/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 151.78% | HC Wainwright & Co. | Andrew Fein | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 48.1% | Truist Securities | Srikripa Devarakonda | → $50 | Initiates | → Buy | Get Alert |
| 06/15/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 42.18% | Stifel | Bradley Canino | → $48 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 6.64% | Credit Suisse | Richard Law | → $36 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 15.52% | Morgan Stanley | James Quigley | $41 → $39 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | KYMR | Buy Now | Kymera Therapeutics | $33.76 | 6.64% | Credit Suisse | Richard Law | $39 → $36 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Kymera Therapeutics (KYMR)?
The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by Truist Securities on March 1, 2024. The analyst firm set a price target for $54.00 expecting KYMR to rise to within 12 months (a possible 59.95% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kymera Therapeutics (KYMR)?
The latest analyst rating for Kymera Therapeutics (NASDAQ: KYMR) was provided by Truist Securities, and Kymera Therapeutics maintained their buy rating.
When was the last upgrade for Kymera Therapeutics (KYMR)?
The last upgrade for Kymera Therapeutics Inc happened on May 5, 2023 when Raymond James raised their price target to $38. Raymond James previously had a market perform for Kymera Therapeutics Inc.
When was the last downgrade for Kymera Therapeutics (KYMR)?
The last downgrade for Kymera Therapeutics Inc happened on January 3, 2024 when B of A Securities changed their price target from $45 to $30 for Kymera Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Kymera Therapeutics (KYMR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kymera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kymera Therapeutics was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
Is the Analyst Rating Kymera Therapeutics (KYMR) correct?
While ratings are subjective and will change, the latest Kymera Therapeutics (KYMR) rating was a maintained with a price target of $41.00 to $54.00. The current price Kymera Therapeutics (KYMR) is trading at is $33.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.